Clinical Supply

The clinical supply chain is unique to itself, distributing to hundreds of study sites, often world-wide. The rapid growth of biological based pharmaceuticals is apparent in clinical trials today, creating even greater demands on clinical logistics practitioners handling biological specimens such as DNA and RNA. Cold Chain IQ provides industry insights exploring how the efficient supply of clinical materials and IMPs is the lynchpin to ensuring patients are dosed on time and clinical trials run efficiently.

56 results
of 6
Contributor: David Robinson
Posted: 29/09/2017
David Robinson
The global clinical trial supplies market is expected generate revenues of US$3.3 billion by 2025 on the back of a sharp rise in the number of complex clinical trial studies, according to a new report by consultancy Grand View Research. Full Content »
Contributor: Pharma IQ
Posted: 14/09/2016
Pharma IQ
In striving to secure the smooth supply of clinical trials, professionals will need a thorough awareness of the chain’s stumbling blocks as well as the respective strategies to best navigate them. With this in mind, Pharma IQ examines the clinical trial supply pain points and the responding technologies and tactics which have the potential to optimise current clinical trial supply practises. Full Content »
Contributor: Cold Chain IQ News
Posted: 13/07/2016
Cold Chain IQ News
Pharma Logistics IQ brings you a rundown of the latest updates and newsworthy developments involving the pharmaceutical logistics around the globe. Full Content »
Contributor: Gary Hutchinson
Posted: 29/06/2016
Gary Hutchinson
Clinical trial material (CTM) or investigational medicinal products (IMP) are an important part of the early stages of the life science supply chain. As trials are being run on a global scale, in markets with less than ideal infrastructure, there is a dire need for companies to work with specialized cold chain experts to engineer and design innovative distribution processes.
Cold chain failure may lead to: the patient being administered an unsafe product; liability based on compliance infractions; inconsistent data results; or an entire shipment’s product integrity could be rejected by the quality department, resulting in costly delays. Full Content »
Contributor: George Clinical Representative
Posted: 23/02/2016
Georger
The number of Phase Ib studies are on the rise as it presents an opportunity to test the drug’s possible effectiveness before launching into a larger and riskier Phase II trial. Clinicaltrials.gov recorded 89 Phase I studies in 2010 globally, with a dramatic increase of 1825 trials in just 4 years. More parties are involved in the conduct of a Phase Ib study, as opposed to a Phase I study, as it includes the Phase I unit, CRO and referring si Full Content »
Contributor: George Clinical Representative
Posted: 18/01/2016
Georger
Globally, there are millions of people that could benefit from an intensive lowering of blood pressure (BP). An individual with lower BP decreases their chances of suffering from any cardiovascular events such as: stroke, heart disease or heart attacks. A new study shows that lowering blood pressure to less than 140 mm Hg, the current treatment standard, had significant benefits. Full Content »
Contributor: Miss Chanice Henry
Posted: 22/12/2015
Miss Chanice Henry
The final quarter of 2015 saw a number of high level collaboration announcements in the pharma space, including the highly anticipated potential Pfizer and Allergan merger. Key advancements were spotted with spacecraft intelligence being pinpointed as one of the latest technologies to propel the cold chain market after it was used to support the ebola vaccine candidates in Sierra Leone.

Here Cold Chain IQ presents the industry’s highlights for this quarter. Full Content »
Posted: 22/12/2015
Top Content For 2015
Cold Chain IQ and Pharma IQ present the top content pieces for 2015 in this annual bumper, so you can browse through some of this year’s best articles to feature on the portals. Full Content »
Posted: 17/11/2015
Planning & Forecasting Considerations in Global Clinical Trial Supply
As identified by Dr. Roberto Torres (1) in a recent article, a high level of potential drugs fail to reach the market during clinical trials – which can incur large financial losses. Alongside a lack of efficacy, safety or economics, both poor planning and a failure to adequately assess the market for planning purposes are marked as key potential d Full Content »
Posted: 29/10/2015
Innovation in Clinical Trial Supply
Innovation is thought to be a keystone in the process of being competitive in any market. Within clinical trial supply, a lack of innovation can be costly in regards to a range of variables.

With this in mind, Pharma IQ discusses the latest trailblazing techniques in the arena with a panel of Clinical Trial Supply specialists. Full Content »
56 results
of 6
Contributor: Shawn Siegel
Posted: 01/05/2013
Cold Chain podcast
Mary Foster is the chair of the USP's committee on Packaging, Storage and Distribution. In this podcast, she discusses the regulatory challenges of transporting and distributing clinical trial materials and biologics, and also her position with Athena Pharma Solutions. Have Your SayRate this feature and give us your feedback in the comments Full Podcast »
Contributor: Gary Hutchinson
Posted: 29/06/2016
Gary Hutchinson
Clinical trial material (CTM) or investigational medicinal products (IMP) are an important part of the early stages of the life science supply chain. As trials are being run on a global scale, in markets with less than ideal infrastructure, there is a dire need for companies to work with specialized cold chain experts to engineer and design innovative distribution processes. Cold chain failure may lead to: the patient being administered an unsafe product; liability based on compliance infractions; inconsistent data results; or an entire shipment’s product integrity could be rejected by the quality department, resulting in costly delays. Full Column »
Contributor: Pharma IQ
Posted: 14/09/2016
Pharma IQ
In striving to secure the smooth supply of clinical trials, professionals will need a thorough awareness of the chain’s stumbling blocks as well as the respective strategies to best navigate them. With this in mind, Pharma IQ examines the clinical trial supply pain points and the responding technologies and tactics which have the potential to optimise current clinical trial supply practises. Full Whitepaper »